康拓医疗总部 ◎记者 张问之 从领着几名初创员工在西安创业园起步，到登陆资本市场，在科创板上市；从寂寂无名，到产品覆盖国 内外众多知名医院，成为国内为数不多能够在细分领域与行业巨头竞争的本土企业……康拓医疗以 PEEK（注：聚醚醚酮，一种高分子材料）材料为核心，实现了中国神经外科植入医疗器械的国产替 代。 上市四年，康拓医疗业务有何拓展？在不断的变革中，哪些核心基因构成了其坚固的"护城河"？近日， 上海证券报记者走进康拓医疗，对话董事长胡立人，探寻这家高科技企业的发展破局之道。 实现颅骨修补国产替代 回望康拓医疗的发展历程，有两个节点性事件对公司影响深远。其一便是国产替代——PEEK材料在高 值耗材领域的应用逐步替代传统钛金属。在这个过程中，康拓医疗抓住机遇，获批首个国产PEEK材料 颅骨修补及固定产品注册证，成功实现国产替代。 多年前，植入式医疗器械的技术和市场都掌握在外国人手里，患者和医院常常要以高额费用从国外采 购。"建立一家中国人自己的植入式医疗器械研发生产企业"的想法在胡立人心中萌芽。 这也锻造了康拓医疗的核心竞争力，即产品研发及创新能力。公司在PEEK注塑、PEEK3D打印、生物 再生材料等工艺和 ...

Group 1 - The core viewpoint of the news is that 康拓医疗 is actively expanding its global presence through its subsidiary BIOPLATE, which is focused on enhancing profitability and market access in various countries [1] - BIOPLATE has significantly reduced its losses in the first half of 2025 compared to the same period last year by improving operational efficiency and diversifying its product line [1] - The company has achieved product market access in nearly 40 countries or regions and plans to expand its team and resources to grow its business scale [1] Group 2 - The PEEK bone plate production line in the United States has officially commenced operations, and the company is actively promoting its products in the market [1] - The management addressed concerns regarding the slight decline in gross margin by implementing aggressive marketing strategies and optimizing production processes to stabilize margins [1] - In the new business areas of oral, thoracic surgery, and maxillofacial repair, the company is expanding its "优贝雅" brand implant system and has acquired equity in 蝾螈生物 to enhance its product offerings in the oral implant market [2]